AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Home > Products > Pozemet

Product List

Pozemet

Generic:

Metformin HCl, Pioglitazone HCl 

 

Therapeutic Class:

Glitazone& Biguanide Combinations

 

Composition:

Pozemet Tab 15 mg/500 mg:

Each tablet contains 15 mg pioglitazone hydrochloride with 500
mg metformin hydrochloride.

Pozemet Tab 15 mg/850 mg:

Each tablet contains 15 mg pioglitazone hydrochloride with 850
mg metformin hydrochloride.

 

Description:

Pozemet tablet contains
two oral antihyperglycemic drugs, pioglitazone hydrochloride and metformin
hydrochloride. They are used in the management of type 2 diabetes.

Pioglitazone
hydrochloride acts primarily by decreasing insulin resistance. It improves
sensitivity to insulin in muscle and adipose tissue and inhibits hepatic
gluconeogenesis. It reduces circulating insulin levels and improves
glycemic control.

Metformin hydrochloride
improves glucose tolerance by lowering both basal and postprandial plasma
glucose. It improves insulin sensitivity by increasing peripheral glucose
uptake and utilization. It also decreases hepatic glucose production and
intestinal absorption of glucose.

 

Indications:

Pozemet is indicated as an adjunct to diet and exercise to
improve glycemic control in type 2 diabetic patients who are already
treated with a combination of pioglitazone and metformin or whose diabetes
is not adequately controlled with metformin alone or for those patients who
have initially responded to pioglitazone alone and require additional
glycemic control.

 

Dosage:


Starting dose of Pozemet should be based on the patient’
s current treatment
of pioglitazone and/or metformin. Pozemet should be given with meals in
divided daily doses to reduce the gastrointestinal side effects associated
with metformin.

Starting Dose:

 

 

For patients inadequately controlled on metformin monotherapy:

Pozemet  may be
initiated at either 15 mg/500 mg or 15 mg/850 mg tablet strength based on
usual starting dose of pioglitazone (15-30 mg daily), once or twice daily
and gradually titrated after assessing adequacy of therapeutic response.

For patients who initially responded to pioglitazone monotherapy & require additional glycemic control:

Pozemet may be
initiated at either 15 mg/500 mg twice daily or 15 mg/850 mg tablet
strength once daily based on the usual starting doses of metformin (500 mg
twice daily or 850 mg daily) and gradually titrated after assessing
adequacy of therapeutic response.

For patients switching from combination therapy of pioglitazone plus metformin as separate tablets:

Pozemet may be
initiated with either 15 mg/500 mg or 15 mg/850 mg tablet strengths based
on the dose of pioglitazone and metformin already being taken.

Maximum Recommended Dose:

The maximum recommended dose for pioglitazone is 45 mg & metformin is 2,550 mg daily in adults.

 

Presentations:

  • Pozemet 15 mg/500 mg is available in 14’s
  • Pozemet 15 mg/850 mg is available in 14’s